Skip to main content
Erschienen in: Medical Microbiology and Immunology 3/2007

01.09.2007 | Original Investigation

Comparison of the neutralizing and ELISA antibody titres to measles virus in human sera and in gamma globulin preparations

verfasst von: Holger F. Rabenau, Branko Marianov, Sabine Wicker, Regina Allwinn

Erschienen in: Medical Microbiology and Immunology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Measles virus infection as well as measles vaccination induces a long-lasting immune protection. Specific antibodies have been proven to be associated with this immune protection, since measles immunity can be transferred by immune globulin application (passive immunisation). The neutralisation test (NT) is regarded as the gold standard method for measles immunity because it measures functional neutralising antibody, while with the ELISA, which is often based on cell culture grown native virus antigens, predominantly antibodies to the nucleoprotein antigen were detected. To compare the results of NT and ELISA 199 individual sera and 364 gamma globulin samples, which were made from plasma pools, were tested. Qualitative results showed that the sensitivity of the ELISA was 141/144 (97.9%) and specificity was 48/55 (87.3%) when compared to the NT and focused to the patient samples. For the gamma globulin samples the sensitivity and specificity was 100%. As expected no measles NT negative plasma pool samples were found. The present study showed that with increasing NT-titre, the ELISA-values also rise. False negative ELISA results were obtained in 1.5% of patient sera, mainly containing low levels of neutralising antibody. In both antibody tests seropositive specimens revealed a quite good to moderate correlation. Taken together, the measles IgG ELISA is adequately for immunity testing and identifying of seronegative individuals for vaccination.
Literatur
1.
Zurück zum Zitat Cohen BJ, Parry RP, Doblas D, Samuel D, Warrener L, Andrews N, Brown D (2006) Measles immunity testing: comparison of two measles IgG ELlSAs with plaque reduction neutralisation assay. J Virol Methods 131:209–212PubMedCrossRef Cohen BJ, Parry RP, Doblas D, Samuel D, Warrener L, Andrews N, Brown D (2006) Measles immunity testing: comparison of two measles IgG ELlSAs with plaque reduction neutralisation assay. J Virol Methods 131:209–212PubMedCrossRef
3.
Zurück zum Zitat Griffin DE (2001) Measles virus. In: Knipe DM, Howley PM (eds) Measles virus in fields virology. Lippincott, Williams & Wilkins, Philadelphia, pp 1401–1441 Griffin DE (2001) Measles virus. In: Knipe DM, Howley PM (eds) Measles virus in fields virology. Lippincott, Williams & Wilkins, Philadelphia, pp 1401–1441
4.
Zurück zum Zitat Hesketh L, Charlett A, Farrington P, Miller E, Forsey T, Morgan-Capner P (1997) An evaluation of nine commercial EIA kits for the detection of measles specific IgG. J Virol Methods 66:51–59 Hesketh L, Charlett A, Farrington P, Miller E, Forsey T, Morgan-Capner P (1997) An evaluation of nine commercial EIA kits for the detection of measles specific IgG. J Virol Methods 66:51–59
5.
Zurück zum Zitat Lee MS, Nokes DJ, Hsu HM, Lu CF (2000) Protective titres of measles neutralising antibody. J Med Virol 62:511–517PubMedCrossRef Lee MS, Nokes DJ, Hsu HM, Lu CF (2000) Protective titres of measles neutralising antibody. J Med Virol 62:511–517PubMedCrossRef
6.
Zurück zum Zitat Markowitz LE, Katz SL (1994) Measles vaccine. In: Plotkin SA, Mortimer EA Jr (eds) Vaccines, 2nd edn. Saunders, Philadelphia, pp 229–76 Markowitz LE, Katz SL (1994) Measles vaccine. In: Plotkin SA, Mortimer EA Jr (eds) Vaccines, 2nd edn. Saunders, Philadelphia, pp 229–76
7.
Zurück zum Zitat Min-Shi L, Cohen BJ, Hand J, Nokes D (1999) A simplified and standardised neutralization enzyme immunoassay for the quantification of measles neutralizing antibody. J Virol Methods 78:209–217CrossRef Min-Shi L, Cohen BJ, Hand J, Nokes D (1999) A simplified and standardised neutralization enzyme immunoassay for the quantification of measles neutralizing antibody. J Virol Methods 78:209–217CrossRef
8.
Zurück zum Zitat Neumann PW, Weber JM, Jessamine AG, O’Shaughnessy MV (1985) Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay and hemagglutination inhibition test with neutralization test for determination of immune status. J Clin Microbiol 22(2):296–298PubMed Neumann PW, Weber JM, Jessamine AG, O’Shaughnessy MV (1985) Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay and hemagglutination inhibition test with neutralization test for determination of immune status. J Clin Microbiol 22(2):296–298PubMed
9.
Zurück zum Zitat Rabenau HF, Weber B (1994) Evaluation of a new automated microneutralization assay for the quantitative detection of neutralizing antibodies against enteroviruses. Zbl Bakt Int J Med Microbiol 280:534–539 Rabenau HF, Weber B (1994) Evaluation of a new automated microneutralization assay for the quantitative detection of neutralizing antibodies against enteroviruses. Zbl Bakt Int J Med Microbiol 280:534–539
10.
Zurück zum Zitat Schmitz H, Essuman S (1986) Comparison of the neutralizing and ELISA antibody titres to human cytomegalovirus (HCMV) in human sera and in gamma globulin preparations. J Med Virol 20(2):177–182PubMedCrossRef Schmitz H, Essuman S (1986) Comparison of the neutralizing and ELISA antibody titres to human cytomegalovirus (HCMV) in human sera and in gamma globulin preparations. J Med Virol 20(2):177–182PubMedCrossRef
11.
Zurück zum Zitat Siedler A, Leitmeyer K (2004) Relevance of sentinel surveillance systems for the implementation and evaluation of vaccination strategies. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47:1136–1143PubMedCrossRef Siedler A, Leitmeyer K (2004) Relevance of sentinel surveillance systems for the implementation and evaluation of vaccination strategies. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47:1136–1143PubMedCrossRef
12.
Zurück zum Zitat van den Hof S, van Gageldonk-Lafeber AB, van Binnendijk RS, van Gageldonk PG, Berbers GA (2003) Comparison of measles virus-specific antibody titres as measured by enzyme-linked immunosorbent assay and virus neutralisation assay. Vaccine 21:4210–4214PubMedCrossRef van den Hof S, van Gageldonk-Lafeber AB, van Binnendijk RS, van Gageldonk PG, Berbers GA (2003) Comparison of measles virus-specific antibody titres as measured by enzyme-linked immunosorbent assay and virus neutralisation assay. Vaccine 21:4210–4214PubMedCrossRef
Metadaten
Titel
Comparison of the neutralizing and ELISA antibody titres to measles virus in human sera and in gamma globulin preparations
verfasst von
Holger F. Rabenau
Branko Marianov
Sabine Wicker
Regina Allwinn
Publikationsdatum
01.09.2007
Verlag
Springer-Verlag
Erschienen in
Medical Microbiology and Immunology / Ausgabe 3/2007
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-007-0037-2

Weitere Artikel der Ausgabe 3/2007

Medical Microbiology and Immunology 3/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.